Sponsor

GBG Forschungs GmbH

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name GBG Forschungs GmbH appears in 56 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials56
Recruiting shown7
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

56 shown
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · lead sponsor · 2024-12-13
RECRUITING
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerNCT06607757 · lead sponsor · 2024-12-04
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · lead sponsor · 2023-01-02
RECRUITING
Long-term Safety and Efficacy of GBG Study ParticipantsNCT05739591 · lead sponsor · 2022-10-12
RECRUITING
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · lead sponsor · 2020-10-28
ACTIVE_NOT_RECRUITING
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerNCT03555877 · lead sponsor · 2018-03-15
COMPLETED
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).NCT03355157 · lead sponsor · 2018-03-01
COMPLETED
Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · lead sponsor · 2017-02-13
COMPLETED
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination DeficiencyNCT02789332 · lead sponsor · 2016-09-01
COMPLETED
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerNCT02685059 · lead sponsor · 2016-06-01
COMPLETED
Dose EScalation Induction of EvERolimusNCT02387099 · lead sponsor · 2015-05-01
COMPLETED
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)NCT02125344 · lead sponsor · 2014-12-01
COMPLETED
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryNCT01864746 · lead sponsor · 2013-10-30
COMPLETED
Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and ExemestaneNCT01773460 · lead sponsor · 2013-07-01
TERMINATED
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)NCT01779479 · lead sponsor · 2013-02-01
COMPLETED
Study of Nab-Paclitaxel in High Risk Early Breast CancerNCT01690702 · lead sponsor · 2012-09-01
COMPLETED
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer PatientsNCT01638247 · lead sponsor · 2012-08-01
COMPLETED
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)NCT01583426 · lead sponsor · 2012-07-01
COMPLETED
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing ChemotherapyNCT01594177 · lead sponsor · 2012-05-01
COMPLETED
Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)NCT01534455 · lead sponsor · 2012-02-01
TERMINATED
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast CancerNCT01426880 · lead sponsor · 2011-08-01
COMPLETED
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)NCT01416558 · lead sponsor · 2011-07-01
TERMINATED
Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast CancerNCT01498458 · lead sponsor · 2010-10-01
COMPLETED
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast CancerNCT01200212 · lead sponsor · 2009-07-01
TERMINATED
Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the BreastNCT01204437 · lead sponsor · 2009-03-01
COMPLETED
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerNCT00548899 · lead sponsor · 2007-11-01
COMPLETED
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerNCT00567554 · lead sponsor · 2007-10-01
COMPLETED
Efficacy of RAD001 in Breast Cancer Patients With Bone MetastasesNCT00466102 · lead sponsor · 2006-12-01
UNKNOWN
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast CancerNCT00661739 · lead sponsor · 2005-07-01
COMPLETED
Mono Efficacy of Capecitabine (MoniCa)NCT00196820 · lead sponsor · 2005-07-01
COMPLETED
Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)NCT00196846 · lead sponsor · 2005-03-01
COMPLETED
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast CancerNCT00288002 · lead sponsor · 2005-01-01
COMPLETED
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant ChemotherapyNCT00512993 · lead sponsor · 2004-12-01
COMPLETED
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)NCT00196872 · lead sponsor · 2004-07-01
COMPLETED
Study in Elderly Patients With Early Breast Cancer (ICE)NCT00196859 · lead sponsor · 2004-06-01
COMPLETED
TBP Study With Capecitabine Plus Minus TrastuzumabNCT00148876 · lead sponsor · 2003-09-01
COMPLETED
Breast Cancer in Pregnancy Register StudyNCT00196833 · lead sponsor · 2003-04-01
UNKNOWN
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast CancerNCT00544765 · lead sponsor · 2002-09-01
COMPLETED
Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)NCT00544232 · lead sponsor · 2002-08-01
COMPLETED
Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)NCT00795899 · lead sponsor · 2002-01-01
COMPLETED
German Preoperative Adriamycin Docetaxel StudyNCT00543829 · lead sponsor · 1998-04-01
COMPLETED
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast CancerNCT00793377 · lead sponsor
COMPLETED
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · collaborator · 2025-12-18
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · collaborator · 2022-12-12
RECRUITING
AXillary Surgery After NeoAdjuvant TreatmentNCT04373655 · collaborator · 2020-04-28
RECRUITING
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · collaborator · 2020-12-04
ACTIVE_NOT_RECRUITING
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · collaborator · 2017-06-21
ACTIVE_NOT_RECRUITING
Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)NCT03102307 · collaborator · 2017-02-01
COMPLETED
Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary SurgeryNCT02466737 · collaborator · 2015-09-01
ACTIVE_NOT_RECRUITING
Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast CancerNCT02481128 · collaborator · 2014-05-01
COMPLETED
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerNCT02032277 · collaborator · 2014-04-02
COMPLETED
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerNCT01816594 · collaborator · 2013-09-03
COMPLETED
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)NCT01772472 · collaborator · 2013-04-03
COMPLETED
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal WomenNCT00545077 · collaborator · 2007-11-06
COMPLETED
Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer PatientsNCT00798070 · collaborator · 2007-02-01
ACTIVE_NOT_RECRUITING
6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer PatientsNCT01222052 · collaborator · 2002-01-01
UNKNOWN

Drugs studied in this sponsor's trials

37 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing GBG Forschungs GmbH as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

ferric carboxymaltose RxCUI 1433693 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial goserelin RxCUI 50610 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ibandronate RxCUI 115264 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial inavolisib RxCUI 2695422 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial palbociclib RxCUI 1601374 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial pembrolizumab RxCUI 1547545 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial Phesgo RxCUI 2382605 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial ribociclib RxCUI 1873916 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sacituzumab govitecan RxCUI 2360232 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial tamoxifen RxCUI 10324 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Xeloda RxCUI 220961 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial zoledronic acid RxCUI 77655 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor42
collaborator14
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.